LAVA Therapeutics (LVTX) Revenue & Revenue Breakdown
LAVA Therapeutics Revenue Highlights
Latest Revenue (Y)
$6.77M
Latest Revenue (Q)
$6.99M
LAVA Therapeutics Revenue by Period
LAVA Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $6.77M | -65.09% |
| 2022-12-31 | $19.39M | 287.82% |
| 2021-12-31 | $5.00M | 27.60% |
| 2020-12-31 | $3.92M | 100.00% |
| 2019-12-31 | - | - |
LAVA Therapeutics generated $6.77M in revenue during NA 2023, up -65.09% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
LAVA Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $6.99M | 1880.74% |
| 2023-12-31 | $353.00K | 566.04% |
| 2023-09-30 | $53.00K | -98.97% |
| 2023-06-30 | $5.14M | 319.85% |
| 2023-03-31 | $1.22M | -53.64% |
| 2022-12-31 | $2.64M | -82.70% |
| 2022-09-30 | $15.26M | 3160.90% |
| 2022-06-30 | $468.00K | -53.20% |
| 2022-03-31 | $1.00M | - |
| 2021-12-31 | $1.00M | -51.59% |
| 2021-09-30 | $2.07M | 93.53% |
| 2021-06-30 | $1.07M | -1.13% |
| 2021-03-31 | $1.08M | -52.07% |
| 2020-12-31 | $2.25M | 132.01% |
| 2020-09-30 | $970.94K | 45.83% |
| 2020-06-30 | $665.80K | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
LAVA Therapeutics generated $6.99M in revenue during Q1 2024, up 1880.74% compared to the previous quarter, and up 264.85% compared to the same period a year ago.
LAVA Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADAG | Adagene | $18.11M | $833.34K |
| IKNA | Ikena Oncology | $9.16M | - |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| LVTX | LAVA Therapeutics | $6.77M | $6.99M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| BNOX | Bionomics | $22.05K | $98.94K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DSGN | Design Therapeutics | - | - |
| RZLT | Rezolute | - | - |
| CCCC | C4 Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| NXTC | NextCure | - | - |
| TIL | Instil Bio | - | - |
| ERAS | Erasca | - | - |
| ELYM | Eliem Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| ACHL | Achilles Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| XLO | Xilio Therapeutics | - | $2.36M |
LVTX Revenue FAQ
What is LAVA Therapeutics’s yearly revenue?
LAVA Therapeutics's yearly revenue for 2023 was $6.77M, representing a decrease of -65.09% compared to 2022. The company's yearly revenue for 2022 was $19.39M, representing an increase of 287.82% compared to 2021. LVTX's yearly revenue for 2021 was $5M, representing an increase of 27.60% compared to 2020.
What is LAVA Therapeutics’s quarterly revenue?
LAVA Therapeutics's quarterly revenue for Q1 2024 was $6.99M, a 1880.74% increase from the previous quarter (Q4 2023), and a 471.24% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $353K, a 566.04% increase from the previous quarter (Q3 2023), and a -86.63% decrease year-over-year (Q4 2022). LVTX's quarterly revenue for Q3 2023 was $53K, a -98.97% decrease from the previous quarter (Q2 2023), and a -99.65% decrease year-over-year (Q3 2022).
What is LAVA Therapeutics’s revenue growth rate?
LAVA Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 35.38%, and for the last 5 years (2019-2023) was 0%.